首页> 外文OA文献 >Safety and Efficacy of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis (MDR-TB)

【2h】

Safety and Efficacy of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis (MDR-TB)

机译：Delamanid治疗耐多药结核病（mDR-TB）的安全性和有效性

页面导航

著录项
相似文献
相关主题

著录项

作者
Stephen K. Field;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Safety and Efficacy of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis (MDR-TB) [J] . Stephen K. Field Clinical Medicine Insights: Therapeutics . 2013,第5期

机译：德拉曼尼德在治疗耐多药结核病（MDR-TB）中的安全性和有效性
2. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial [J] . Myungsun Lee, Jeongha Mok, Deog Kyeom Kim, Trials . 2019,第1期

机译：Delamanid，Linezolid，Levofloxacin和吡嗪酰胺用于治疗含氟喹诺酮类敏感多药结核患者（使用现有和新药物治疗MDR-TB的治疗缩短）：研究协议II / III，多中心，随机，开放标签临床试验
3. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial [J] . von Groote-Bidlingmaier Florian, Patientia Ramonde, Sanchez Epifanio, The lancet. Respiratory medicine. . 2019,第3期

机译：Delamanid与优化的背景方案结合治疗多药抗性结核的优化疗效和安全性：多期，随机，双盲，安慰剂控制，并联组第3阶段试验
4. The Complex Treatment with Mellozan Immunomodulator of Patients with Multidrug-Resistant Tuberculosis [C] . Sain D., Cula E., Nepoliuc L., World Asthma and COPD Forum . 2010

机译：多药抗性结核病患者Mellozan免疫调节器的复杂处理
5. Correlates of treatment outcomes of Multidrug-Resistant Tuberculosis (MDR-TB): a systematic review and meta-analysis. [D] . Akcakir, Yasemin. 2009

机译：耐多药结核病（MDR-TB）治疗结果的相关性：系统评价和荟萃分析。
6. Delamanid linezolid levofloxacin and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs MDR-END): study protocol for a phase II/III multicenter randomized open-label clinical trial [O] . Myungsun Lee, Jeongha Mok, Deog Kyeom Kim, 2019

机译：地拉曼尼利奈唑胺左氧氟沙星和吡嗪酰胺用于治疗氟喹诺酮敏感性耐多药结核病（使用现有药物和新药治疗MDR-TB缩短MDR-END）：II / III期多中心随机开放标签的临床试验
7. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial [O] . Myungsun Lee, Jeongha Mok, Deog Kyeom Kim, 2019

机译：Delamanid，Linezolid，Levofloxacin和吡嗪酰胺用于治疗含氟喹诺酮类敏感多药结核患者（使用现有和新药物治疗MDR-TB的治疗缩短）：研究协议II / III，多中心，随机，开放标签临床试验

Safety and Efficacy of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis (MDR-TB)

著录项

相似文献

相关主题

期刊订阅